Bluejay Diagnostics Stock Performance
| BJDX Stock | USD 1.62 0.06 3.85% |
The firm shows a Beta (market volatility) of -3.16, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Bluejay Diagnostics are expected to decrease by larger amounts. On the other hand, during market turmoil, Bluejay Diagnostics is expected to outperform it. Bluejay Diagnostics right now shows a risk of 18.37%. Please confirm Bluejay Diagnostics skewness, and the relationship between the value at risk and day median price , to decide if Bluejay Diagnostics will be following its price patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Bluejay Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly fragile fundamental indicators, Bluejay Diagnostics may actually be approaching a critical reversion point that can send shares even higher in July 2025. ...more
| Begin Period Cash Flow | 2.2 M |
Bluejay Diagnostics Relative Risk vs. Return Landscape
If you would invest 373.00 in Bluejay Diagnostics on March 31, 2025 and sell it today you would lose (211.00) from holding Bluejay Diagnostics or give up 56.57% of portfolio value over 90 days. Bluejay Diagnostics is currently generating 0.1122% in daily expected returns and assumes 18.367% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Bluejay, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bluejay Diagnostics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bluejay Diagnostics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bluejay Diagnostics, and traders can use it to determine the average amount a Bluejay Diagnostics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0061
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | BJDX |
| Negative Returns |
Estimated Market Risk
| 18.37 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.11 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bluejay Diagnostics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bluejay Diagnostics by adding Bluejay Diagnostics to a well-diversified portfolio.
Bluejay Diagnostics Fundamentals Growth
Bluejay Stock prices reflect investors' perceptions of the future prospects and financial health of Bluejay Diagnostics, and Bluejay Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bluejay Stock performance.
| Return On Equity | -2.01 | ||||
| Return On Asset | -0.8 | ||||
| Current Valuation | (508.15 K) | ||||
| Shares Outstanding | 1.49 M | ||||
| Price To Book | 0.63 X | ||||
| Price To Sales | 54.99 X | ||||
| EBITDA | (6.7 M) | ||||
| Cash And Equivalents | 15.34 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 222.25 K | ||||
| Debt To Equity | 0.04 % | ||||
| Book Value Per Share | 6.98 X | ||||
| Cash Flow From Operations | (7.82 M) | ||||
| Earnings Per Share | 277.20 X | ||||
| Total Asset | 6.66 M | ||||
| Retained Earnings | (34.67 M) | ||||
About Bluejay Diagnostics Performance
Evaluating Bluejay Diagnostics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Bluejay Diagnostics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bluejay Diagnostics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts. Bluejay Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.Things to note about Bluejay Diagnostics performance evaluation
Checking the ongoing alerts about Bluejay Diagnostics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bluejay Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bluejay Diagnostics had very high historical volatility over the last 90 days | |
| Bluejay Diagnostics may become a speculative penny stock | |
| Bluejay Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (7.72 M) with profit before overhead, payroll, taxes, and interest of 48.91 K. | |
| Bluejay Diagnostics currently holds about 15.34 M in cash with (7.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Bluejay Diagnostics has a frail financial position based on the latest SEC disclosures |
- Analyzing Bluejay Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bluejay Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining Bluejay Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bluejay Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bluejay Diagnostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bluejay Diagnostics' stock. These opinions can provide insight into Bluejay Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Bluejay Stock Analysis
When running Bluejay Diagnostics' price analysis, check to measure Bluejay Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluejay Diagnostics is operating at the current time. Most of Bluejay Diagnostics' value examination focuses on studying past and present price action to predict the probability of Bluejay Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluejay Diagnostics' price. Additionally, you may evaluate how the addition of Bluejay Diagnostics to your portfolios can decrease your overall portfolio volatility.